VivoSeq
Other

Advanced

0

Pipeline Programs↗

41

Active Trials↗

45

Companies Involved↗

Advanced is an early-stage landscape with 0 programs across 45 companies. The most active players are AstraZeneca, Coordination Pharmaceuticals, Inc., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

30/100

Mech. Concentration

N/A

Completion Rate

74/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalC

Coordination Pharmaceuticals, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBeiGene logo

BeiGene

0 programs

PreclinicalL

LaNova Medicines Limited

0 programs

PreclinicalD

Deciphera Pharmaceuticals, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

164

clinical trials

Completed69 · 42%
Unknown status30 · 18%
Recruiting27 · 16%
Terminated18 · 11%
Active, not recruiting9 · 5%
Withdrawn6 · 4%
Other5 · 3%

Clinical Trials

Trial Activity

164 trials

Study of IMC-P115C in Advanced PRAME-Positive Cancers
Recruiting·IImmunocore Ltd·Phase 1·NCT07156136·140 enrolled
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
Recruiting·UUniversity of Arizona·Phase 3·NCT04062565·20 enrolled
The Use of Advanced Imaging in HFpEF
Recruiting·SSheffield Teaching Hospitals NHS Foundation Trust·N/A·NCT06905405·40 enrolled
Odronextamab in Low Tumor Volume Advanced FL
Recruiting·GGottfried von Keudell, MD PhD·Phase 2·NCT07128641·35 enrolled
Phase 2 Study of WGI-0301 for Advanced HCC
Recruiting·ZZhejiang Haichang Biotech Co., Ltd.·Phase 2·NCT06309485·60 enrolled
Trop-2 Targeted PET Probes in Advanced TNBC
Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT07046455·20 enrolled
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Recruiting·IImmune System Key Ltd·Phase 1·NCT04365179·18 enrolled
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Recruiting·FFudan University·Phase 2·NCT06914674·30 enrolled
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Recruiting·SSichuan Cancer Hospital and Research Institute·N/A·NCT06361589·200 enrolled
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Recruiting·OOmico·Phase 2·NCT06003621·96 enrolled
A Study of AL58805 in Patients With Advanced Tumors
Recruiting·AAdvenchen Laboratories Nanjing Ltd.·Phase 1·NCT07179081·40 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Recruiting·BeiGene logoBeiGene·Phase 1·NCT06257264·258 enrolled
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07157969·300 enrolled
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Recruiting·FFBD Biologics Limited·Phase 1·NCT06487624·50 enrolled
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT07327034·141 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)